Silverarc Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Silverarc Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$599K	–	80
2023 Q4	$599K	Buy	+10,000	New	+$507K	0.18%	62
2022 Q3	–	Sell	-129,795	Closed	-$5.87M	–	82
2022 Q2	$5.87M	Buy	129,795 +24,427	+23%	+$1.11M	1.81%	19
2022 Q1	$5.35M	Buy	+105,368	New	+$4.65M	2.22%	11
2021 Q3	–	Sell	-7,009	Closed	-$443K	–	85
2021 Q2	$443K	Buy	+7,009	New	+$362K	0.2%	84

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silverarc Capital Management's APLS Position: Q1 2024 in Review

Silverarc Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 10,000 shares — an estimated $599K sold.

Silverarc Capital Management first reported a position in APLS in Q2 2021 and held it in 4 quarters. The position peaked at $5.87M in Q2 2022. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

Silverarc Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Silverarc Capital Management sold 10,000 Apellis Pharmaceuticals shares in Q1 2024, an estimated $599K.
Silverarc Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Silverarc Capital Management's Apellis Pharmaceuticals position peaked at $5.87M in Q2 2022.
302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.